Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

Introduction: In the era of multidrug-resistant, extensively drug-resistant (XDR) and even
pandrug-resistant Gram-negative microorganisms, the medical community is facing the …

The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …

Acinetobacter baumannii is a multi-drug resistant opportunistic pathogen, which causes
respiratory and urinary tract infections. Its prevalence increases gradually in the clinical …

Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …

Acinetobacter is a complex genus, and historically, there has been confusion about the
existence of multiple species. The species commonly cause nosocomial infections …

Acinetobacter occupies an important position in nature because of its ubiquitous presence in
diverse environments such as soils, fresh water, oceans, sediments, and contaminated sites …

Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide.
Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents …

Background Nephrotoxicity and neurotoxicity are commonly associated with polymyxin
treatment; however, the emergence of multidrug-resistant Gram-negative bacteria with …

Objectives This study aimed to compare the efficacy and safety of combination therapy with
high-dose sulbactam or colistin with additional antibacterial agents for treating multidrug …